LENZ

LENZ Therapeutics, Inc.

$4.10

-4.43%
SectorHealthcareIndustryBiotechnologyCountryUnited States

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Source: Yahoo Finance
AI summary

Price & performance

1M+12.5%
3M-23.5%
YTD-74.4%
1Y-82.3%
52-week range—
Beta1.67
Full chart and returns against a benchmark

Q-Score

36/ 100

Quality against peers; 50 is the peer median.

Growth29
Risk49
Performance34
Valuation38
Profitability37
Leverage53
Sentiment63
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$19.1M
Net income-$82.1M
Net margin-430.3%
Historical fundamentals

Revenue exposure

Largest customer18%
Regions, segments, customers and suppliers

Valuation

LENZIndustryP/E—89.69P/S10.4211.88EV/EBITDA—67.10P/B0.676.22PEG—4.02
Dividend yield0.00%
Every valuation metric

Earnings

Oct 29next report, before the open
EPS estimate$-0.98
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate